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Abstract
Background
The Americas were the last continent colonized by humans carrying malaria parasites. Plas-
modium falciparum from the New World shows very little genetic diversity and greater link-
age disequilibrium, compared with its African counterparts, and is clearly subdivided into
local, highly divergent populations. However, limited available data have revealed extensive
genetic diversity in American populations of another major human malaria parasite, P.
vivax.
Methods
We used an improved sample preparation strategy and next-generation sequencing to char-
acterize 9 high-quality P. vivax genome sequences from northwestern Brazil. These new
data were compared with publicly available sequences from recently sampled clinical P.
vivax isolates from Brazil (BRA, total n = 11 sequences), Peru (PER, n = 23), Colombia
(COL, n = 31), and Mexico (MEX, n = 19).
Principal findings/Conclusions
We found that New World populations of P. vivax are as diverse (nucleotide diversity π
between 5.2 × 10−4 and 6.2 × 10−4) as P. vivax populations from Southeast Asia, where
malaria transmission is substantially more intense. They display several non-synonymous
nucleotide substitutions (some of them previously undescribed) in genes known or sus-
pected to be involved in antimalarial drug resistance, such as dhfr, dhps, mdr1, mrp1, and
mrp-2, but not in the chloroquine resistance transporter ortholog (crt-o) gene. Moreover, P.
vivax in the Americas is much less geographically substructured than local P. falciparum
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populations, with relatively little between-population genome-wide differentiation (pairwise
FST values ranging between 0.025 and 0.092). Finally, P. vivax populations show a rapid
decline in linkage disequilibrium with increasing distance between pairs of polymorphic
sites, consistent with very frequent outcrossing. We hypothesize that the high diversity of
present-day P. vivax lineages in the Americas originated from successive migratory waves
and subsequent admixture between parasite lineages from geographically diverse sites.
Further genome-wide analyses are required to test the demographic scenario suggested by
our data.
Author summary
Plasmodium vivax is the most common human malaria parasite in the Americas, but how
and when this species arrived in the New World remains unclear. Here we describe high-
quality whole-genome sequence data for nine P. vivax isolates from Brazil, a country that
accounts for 37% of the malaria burden in this continent, and compare these data with
additional publicly available P. vivax genomes from Brazil, Peru, Colombia, and Mexico.
P. vivax populations from the New World were found to be as diverse as their counter-
parts from areas with substantially higher malaria transmission, such as Southeast Asia,
and to carry several non-synonymous substitutions in candidate drug-resistance genes.
Moreover, genome-wide patterns of linkage disequilibrium between pairs of polymorphic
sites are consistent with very frequent outcrossing in these populations. Interestingly,
local P. vivax is more polymorphic, with less between-population differentiation, than
sympatric populations of P. falciparum, possibly as a result of different demographic histo-
ries of these two species in the Americas. We hypothesize that local P. vivax lineages origi-
nated from successive migratory waves and subsequent admixture between parasites from
geographically diverse sites.
Introduction
Plasmodium vivax is the human malaria parasite with the widest global distribution and
accounts for nearly half of the combined malaria burden in South and Southeast Asia, Oceania,
and Central and South America. Over one-third of the world’s population is currently at risk
of infection with this species, with 16 million clinical cases recorded each year [1]. Although P.
vivax has most likely evolved from parasites that infect chimpanzees and gorillas in sub-Saha-
ran Africa [2,3], it is nowadays rare in most of this continent, where human populations lack a
key erythrocyte receptor for host cell invasion by blood-stage parasites, the Duffy antigen/
receptor for chemokines (DARC) [4]. Where both species coexist, P. vivax typically causes less
severe cases and fewer deaths than P. falciparum, the most virulent human malaria parasite,
but represents a major challenge for ongoing malaria elimination efforts worldwide [1].
The Americas were the last continent colonized by humans carrying malaria parasites, but
the dates and routes of migration of P. vivax to the New World are still debated [5–7]. Archae-
ological evidence for infection with this parasite in indigenous, pre-Columbian populations is
currently limited to a single report of P. vivax antigens being visualized by immunohistochem-
istry in the liver and spleen of South American mummies dating from 3,000 to 600 years ago
[8]. Interestingly, specific antibodies failed to detect P. falciparum antigens in these same sam-
ples [8]. These findings are consistent with the hypothesis that P. vivax, but not P. falciparum,
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was brought to the New World by early human migrations from East Asia or the Western
Pacific [5], but more specific molecular techniques are required to confirm them [9]. Never-
theless, present-day New World populations of P. vivax appear to be more closely related to
extant African and South Asian parasites and now extinct European lineages than to East
Asian and Melanesian strains [10–12], consistent with much more recent parasite migrations
with European conquerors and African slaves during the colonial era [7,13].
Clinical isolates from Brazil are underrepresented in global genomic analyses of P. vivax
[11,14]. However, this country contributes 37% of the malaria burden in the Americas, a
region with over 20 million people at high risk of infection [1]. Obtaining large amounts of
host-free P. vivax DNA from clinical samples from Brazil has been a major challenge for
genome sequencing projects, because (a) blood-stage parasite densities are typically very low
[15], (b) clinical blood samples are heavily contaminated with human DNA from leukocytes,
and (c) methods for long-term in vitro propagation of P. vivax are neither practical nor widely
reproducible [16–18]. Here, we combined an improved sample preparation strategy, for reduc-
ing human DNA contamination and increasing target parasite’s DNA yield, with next-genera-
tion genome re-sequencing to examine a local population of P. vivax from the Amazon Basin
of Brazil. Our nine high-quality genome sequences were compared to those previously
obtained from four countries (Brazil [BRA], Peru [PER], Colombia [COL], and Mexico
[MEX]) [11,14] to reveal local and regional patterns of diversity and differentiation in extant
P. vivax populations from the New World.
Methods
Ethics statement
Study protocols were approved by the Institutional Review Board of the Institute of Biomedical
Sciences, University of São Paulo, Brazil (936/CEP, 2010 and 1183/CEPSH, 2014). Written
informed consent was obtained from all patients.
Sample collection
Parasite samples were collected between November 2012 and June 2013 in eastern Acre and
southern Amazonas, Amazon Basin of Brazil, close to the borders with Peru and Bolivia.
Malaria epidemiology in the study sites has been characterized in detail elsewhere [15,19].
Venous blood samples (10 ml) were collected from eight adult patients attending malaria clin-
ics in the town of Acrelaˆndia, Acre (9˚43’ S, 66˚53’ W), and one adult patient living in the
farming settlement of Remansinho, Amazonas (9˚40’ S-9˚43’ S, 66˚52’ W -66˚59’ W), 120 km
east of Acrelaˆndia (Fig 1). P. vivax infection was diagnosed by on-site microscopy and later
confirmed by qPCR as described below.
Leukocyte depletion and sample cryopreservation
We adapted BioR 01 Plus leukocyte-depletion filters (Fresenius Kabi, Bad Homburg, Ger-
many; S1A Fig) to process 10 to 50-ml volumes of venous blood in our field laboratory in the
Amazon [20]. The per-unit cost of these filters in Brazil is around US$ 25. We first cut off
under sterile conditions, with a scissor, the tubing that connects the filtering device to the
400-ml blood storage bag and to the adapter (S1B and S1C Fig). S1D Fig shows how the filter-
ing device was used in a laminar flow hood; briefly, a 10-ml syringe was used to apply blood
treated with acid citrate dextrose anticoagulant, while a second 10-ml syringe was adapted to
the end of the remaining tubing to recover the filtered, leucocyte-depleted material, which was
transferred to 50-ml sterile centrifuge tubes. No priming with saline was required. After the
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filtration process, the leukocyte depletion device was washed through with at least twice the
volume of RPMI medium as the original blood sample to recover red blood cells (RBCs) that
had been retained in the filter and tubing. Next, the mixture of filtered blood and RPMI
medium recovered in 50-ml tubes was centrifuged at 800 g for 5 minutes and the supernatant
(plasma plus RPMI medium) was removed with a sterile Pasteur pipette.
For cryopreservation, the RBC pellet was resuspended dropwise in Glycerolyte-57 solution
(Fenwall, Fresenius Kabi), at the proportion of 1.66 ml of Glycerolyte for each 1 ml of cell
pellet, under gentle agitation. One ml aliquots of the RBC-Glycerolyte mixture were trans-
ferred to screw-capped cryovials and placed in a Nalgene Mr. Frosty freezing container
Fig 1. Map showing the sampling locations of the New World P. vivax isolates analyzed in this study, comprising Brazil, Peru,
Colombia, and Mexico. The insert shows the study sites in northwestern Brazil (Acrelaˆndia and Remansinho, 120 km apart), close to the
border with Bolivia and Peru. Adapted from [15] and https://commons.wikimedia.org/wiki/Atlas_of_the_world#/media/File:BlankMap-
World6.svg.
https://doi.org/10.1371/journal.pntd.0005824.g001
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(ThermoFisher Scientific, Waltham, MA) that was kept at -80˚C for 24 hours. The next day,
cryovials were plunged in liquid nitrogen for long-term storage. Samples were shipped to São
Paulo in liquid nitrogen, for subsequent schizont maturation.
Short-term in vitro culture for P. vivax schizont maturation and
chloroquine resistance testing
For sample thawing, cryovials were removed from the liquid nitrogen and maintained for 1
min at room temperature (20–25˚C) and 1 min at 37˚C. The 1-ml samples were then trans-
ferred to 50-ml centrifuge tubes, gently mixed with 200 μl of 12% NaCl solution, and let stand
for 1 minute. Next, 10 ml of 1.6% NaCl were gently added, the mixture was gently agitated,
and centrifuged at 180 g for 8 min [21]. After removing the supernatant, the RBC pellet was
washed twice in incomplete McCoy’s 5A medium supplemented with glucose (0.5% w/v),
HEPES (25 mM), and hypoxantine (0.005% w/v), and resuspended in complete McCoy
medium (as above but supplemented with 25% AB+ heat-inactivated human serum) to a final
hematocrit of 2%. Short-term culture in vitro was carried in flat-bottomed dishes placed in a
gas chamber with controlled O2 and CO2 levels that was kept at 37˚C for up to 48 hours. Para-
site growth and maturation were monitored as described [17].
Chloroquine resistance (CQR) was evaluated using an ex-vivo schizont maturation assay in
selected P. vivax samples with> 1,000 parasites/μl of blood and> 50% ring stages at the time
of thawing [22]. There is no consensus regarding the 50% inhibitory concentration (IC50)
indicative of CQR in P. vivax; suggested cut off values range between 100 nM [23] and 220 nM
[24], but all IC50 values in our samples were < 50 nM (Table 1).
DNA isolation and quantification of human and P. vivax DNA with real-
time PCR
DNA templates were isolated from 200-μl aliquots of either whole venous blood (before leuko-
cyte removal) or RBC pellet (after leukocyte removal) using QIAamp DNA blood kits (Qiagen,
Table 1. Field-collected Plasmodium vivax isolates from Brazil with nuclear genomes newly sequenced in this study and summary of sequencing
statistics.
Isolate Sitea Date of
collection
IC50 for
CQb(mM)
No. reads (×
106)
Percent reads
mapped to Sal-Ic
Average sequence
depth
Percent Sal-I
genome covered
No.
SNPsd
17 Acrelaˆndia Jun/13 11.3 17.85 95% 49.79× 84% 6445
18 Acrelaˆndia Dec/12 - -e 23.40 93% 59.35× 85% 6232
19 Acrelaˆndia Nov/12 11.1 23.87 95% 71.93× 86% 5524
20 Acrelaˆndia Apr/13 14.5 18.80 93% 58.91× 89% 6188
32 Acrelaˆndia Jun/13 20.5 22.51 92% 69.09× 93% 5528
51 Acrelaˆndia Jun/13 - - 20.93 94% 58.24× 83% 5819
52 Acrelaˆndia Jun/13 - - 21.43 94% 62.90× 89% 6158
207 Remansinho Apr/13 46.7 21.08 95% 70.13× 89% 6041
ACR Acrelaˆndia Nov/12 20.9 21.04 93% 78.65× 92% 5414
Average 21.21 94% 64.33× 88% 5927.7
aSample collection sites are shown in Fig 1.
b50% inhibitory concentration for chloroquine (CQ) determined by ex-vivo schizont maturation test.
cSal I = reference assembled genome, P. vivax monkey-adapted strain Sal 1 [61]
dNumber of remaining high-quality single-nucleotide polymorphisms (SNPs) after applying the quality filters described in the main text.
e
--not determined.
https://doi.org/10.1371/journal.pntd.0005824.t001
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Hilden, Germany). To estimate the relative proportion of human and parasite DNA, we used
SYBR Green qPCR targeting single-copy genes coding for human topoisomerase III and P.
vivax aldolase. Each 15 μl qPCR mixture contained 2 μl of template DNA, 7.5 μl of 2× Maxima
SYBR Green qPCR master mixture (Fermentas, Burlington, Canada) and 0.3 μM of each of the
primer pairs, Pvaldo-F (GAC AGT GCC ACC ATC CTT ACC) plus Pvaldo-R (CCT TCT
CAA CAT TCT CCT TCT TTC C) and Top3-F (CAT GTT TGA GCT GAG CCT GA) plus
Top3-R (CCA CAC CAC ACC CCT AAC TT). Standard curves were prepared with serial ten-
fold dilutions of a plasmid containing both target sequences to allow for copy number quanti-
tation (number of amplicons/μl of blood). We used a Step One Plus Real-Time PCR System
(Applied Biosystems, Foster City, CA) for PCR amplification with a template denaturation
step at 95˚C for 10 min, followed by 40 cycles of 15 sec at 95˚C and 1 minute at 60˚C, with
fluorescence acquisition at the end of each extension step. Amplification was followed by a
melting program consisting of 15 sec at 95˚C, 15 sec at 60˚C, and a stepwise temperature
increase of 0.2˚C/sec until 95˚C, with fluorescence acquisition at each temperature transition.
All reactions were made in triplicate. We measured parasite DNA enrichment as the parasite:
human copy-number ratio after filtering divided by parasite:human copy-number ratio before
filtering. To estimate the proportion of host and parasite DNA in each sample, we considered
the amplicon copy numbers and the genome size of humans (3.2 Gb) and P. vivax (26.8 Mb;
Sal-I assembly); the DNA content in each copy of the human genome corresponds approxi-
mately to that of 119 copies of the P. vivax genome.
DNA library preparation and whole-genome sequencing
Parasite DNA templates were quantified by fluorometry using a Qubit 3.0 fluorometer (Invi-
trogen, Carlsbad, CA) and sequenced using Ion Torrent Personal Genome Machine (PGM)
and Ion Proton platforms (Life Technologies, Foster City, CA) at the Unit of Computational
Genomics, Laboratory of Bioinformatics, National Laboratory of Scientific Computation, Bra-
zil. Separate libraries were prepared for each sequencing platform, using 1 μg of template DNA
per isolate. DNA samples were sheared using the Bioruptor UCD-200 TS (Diagenode, Liege,
Belgium) sonication system until fragment sizes of 200 bp (for Ion PGM libraries) or 150 bp
(for Ion Proton libraries) were obtained. Libraries were prepared using the Ion Xpress Plus
Fragment Library kit, with Ion Xpress Barcode adapters according to the Ion Xpress Plus
gDNA Fragment Library Preparation protocol (Life Technologies). Size selection was per-
formed on E-Gel SizeSelect 2% agarose gels using the E-Gel iBase Power System (Thermo-
Fisher Scientific). Emulsion PCR was done on the Ion OneTouch 2 system (Life Technologies)
with the Ion PGM Template OT2 200 kit or the Ion PI Template OT2 200 kit version 2 for Ion
PGM and Ion Proton, respectively, following the manufacturer’s instructions (Life Technolo-
gies). Ion PGM libraries were loaded on Ion318 chips v2 and sequenced using the Ion PGM
Sequencing 200 kit v2; Ion Proton libraries were loaded on Ion PI chips v2 and sequenced
using the Ion PI Sequencing 200 kit v2 (Life Technologies). All samples were sequenced on
both platforms; sequence reads (150–200 bp) from two runs in each platform were merged
into a single fastq file per sample.
Additional genomic data sets
To place our genomic data in a regional context, we reanalyzed raw paired-end Illumina reads
from 107 additional P. vivax clinical isolates from the Americas. Fastq files were downloaded
from the Sequence Read Archive (SRA) of the National Center for Biotechnology Information,
United States, and processed in the same way as our newly obtained sequences. Three clinical
isolates from Brazil had sequence data generated on an Illumina Genome Analyzer II platform
Plasmodium vivax genomes from the New World
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at the Welcome Trust Sanger Institute (Hinxton, Cambridge, UK), as part of the P. vivax
genome variation project coordinated by the MalariaGEN network [14]. Other isolates—20
from Brazil, 34 from Peru, 31 from Colombia, and 19 from Mexico—had whole-genome
sequence data generated on an Illumina HiSeq 2000 platform at the Broad Institute of MIT
and Harvard (Cambridge, MA, USA), as part of the International Centers of Excellence for
Malaria Research (ICEMR) program [11]. All isolates from Brazil sequenced in these two pre-
vious studies were collected in endemic areas surrounding Acrelaˆndia, Acre State, between
2008 and 2011.
Single-nucleotide polymorphism (SNP) calling
Fastq files were first filtered for quality; 8 SRA samples were excluded from further analysis
because of mean quality scores 30 (expected base call accuracy 99.9%). We next mapped
the high quality reads onto the PlasmoDB version 10.0 of the Sal-1 reference (http://plasmodb.
org/common/downloads/release-10.0/PvivaxSal1/fasta/data/PlasmoDB-10.0_PvivaxSal1_
Genome.fasta) [25], using Bowtie2 version 2.2.6 [26] with the “very sensitive” preset, allowing
one mismatch per seed region; 11 SRA samples were excluded at this stage because of< 60%
mapping over the reference. The resulting alignments were merged into BAM files with SAM-
tools [27], duplicate reads were identified and marked using the Picard version 2.0.1 MarkDu-
plicates tool, and files were indexed with SAMtools.
We used GATK version 2.0 [28] for SNP calling following the GATK Best Practices
(https://software.broadinstitute.org/gatk/best-practices/). GATK UnifiedGenotyper with the
BaseAlignmentQuality option was used to obtain high-confidence SNPs by applying stringent
VariantFiltration criteria: (a) coverage > 20×, (b) mapping quality > 30, (c) base quality > 30,
read depth and allelic fraction by sample 1, and (d) haplotype score 3. We removed all
SNPs with> 2 alleles and those with minor allele frequency < 0.01 (reads counted across all
sequenced samples).
SnpEff [29] was used to identify SNPs mapping to coding sequences (further classified as
synonymous or nonsynonymous), introns, and intergenic regions of the Sal-I reference
genome. The resulting catalogue of 94,122 high-confidence SNPs was used to genotype each
individual sample using GATK UnifiedGenotyper with default parameters except for the mini-
mum phred-scaled confidence threshold, with a calling variant = 50 and emitting variant = 10.
Heterozygote calls were converted to the majority allele if75% of the reads in that sample
were the majority allele; otherwise, the allele was undetermined. Sites with < 5× coverage in a
given sample were filtered out at this stage.
The final data set of P. vivax nuclear genome sequences from the New World comprised
our 9 newly sequenced samples from BRA and 75 high-quality SRA samples (2 from BRA, 23
from PER, 31 from COL, and 19 from MEX); 13 SRA samples were removed during the geno-
typing process because the number of SNPs identified (range: 13 to 2,889) was below the pre-
defined minimum of 3,000 nucleotide differences compared to the Sal-I reference, consistent
with poor sequencing coverage. Overall, we excluded 21 (out of 23) SRA samples from BRA
and 11 (out of 34) SRA samples from PER at different stages of this analysis. Isolate codes and
SRA accession numbers of samples used in this analysis are given in S1 Table.
Within-population genetic diversity and recombination
The average pairwise nucleotide diversity (π, average number of nucleotide differences per site
between pairs of DNA sequences) was calculated within each geographic population using
VCFtools [30]. Values were plotted, using R version 3.3.0, as moving averages within 1-kb slid-
ing windows across each chromosome. We recalculated π after masking out subtelomeric
Plasmodium vivax genomes from the New World
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regions and three hypervariable internal chromosome regions (containing sera, msp-3, and
msp-7 gene families) that were more prone to sequence misalignments and poor read mapping
in a previous analysis [14]. The coordinates of these regions are given in the Supplementary
Table 2 of Pearson et al. [14].
Similarly, Tajima’s D values [31] were calculated using VCFtools; mean Tajima’s D across
1-kb windows were plotted for each population. Frequency distributions of π and Tajima’s D
values within 1-kb windows were plotted for each population. We defined windows with the
top 50 π values within each population as highly variable genomic regions. We defined as outli-
ers the 1-kb windows with the 50 highest and 50 lowest mean Tajima’s D values within each
population. We also examined the minor allele frequency (MAF) spectrum separately in each
population.
We next estimated, for each population, the rate at which pairwise linkage disequilibrium
(LD) decreased with increasing physical distance between SNPs due to meiotic recombination.
The squared correlation coefficient r2 between pairs of SNPs of varying distance across the
same chromosome was measured using VCFtools; r2 values were binned by distance (50-bp
windows) and medians within each window were plotted against physical distance between
SNPs. The level of background LD between unlinked markers within each population was esti-
mated by calculating median r2 between all pairs of SNPs on different chromosomes.
Between-population genetic differentiation and population structure
The Wright’s fixation index FST, a measure of population differentiation due to genetic struc-
ture [32], was calculated with VCFtools for each SNP in every pairwise comparison of popula-
tions. Values were averaged across all SNPs to estimate overall pairwise differentiation
between populations. The 100 SNPs with the highest average FST values across all populations
were further characterized.
To assess population structure, we first used the PLINK software (https://www.cog-
genomics.org/plink2 [33]) to carry out principal component analysis (PCA); up to 10 compo-
nents were analyzed. For phylogenetic analysis, a neighbor-joining tree was constructed via
the maximum composite likelihood substitution model with 1,000 bootstrap pseudoreplicates
using MEGA 7.0 (http://www.megasoftware.net/). To estimate the ancestry shared between
individual isolates, we used the ADMIXTURE software package [34] with either all 94,122
high-quality SNPs or a curtailed set of 12,762 SNPs that are not linked. To this end, we
removed each SNP that had an r2 value > 0.1 with any other SNP within a 60-SNP sliding win-
dow advanced by 10 SNPs each time. The optimal number of clusters (K) was determined by
performing multiple runs of the software under different K values (2–10) and selecting the K
values (K = 2 and K = 3) associated with the lowest cross-validation error compared to other K
values (S2 Fig).
Data availability
The sequence data supporting the conclusions of this article are available in the Sequence Read
Archive of the National Center for Biotechnology Information, United States; accession num-
bers are provided in S1 Table.
Results and discussion
Sample preparation and genome sequencing
We designed a single-step procedure to reduce human DNA content in P. vivax-infected
blood using commercially available leukocyte-depletion filters (S1 Fig). Leucocyte depletion in
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17 clinical samples, with initial parasitemias ranging between 854 and 43,177 (median: 7,566)
parasites/μl, decreased the percent human DNA content from a median of 99.2% (range: 82.7–
99.9%) to 23.3% (range: 0–97.6%). No human DNA could be detected by quantitative real-
time polymerase chain reaction (qPCR) in three filtered samples (i.e., 0% host DNA contami-
nation). The residual human DNA content in our leukocyte-depleted samples was similar to
the median of 33.9% (range: 1.6–68.6%) found in blood samples from Indonesia after double
filtration through CF-11 cellulose columns [17]. The increase in parasite:human DNA ratio
after leukocyte depletion ranged between 1.7 and 3,060-fold (median: 227-fold) and appeared
to be inversely proportional to the initial, pre-treatment parasite:human DNA ratio (Spearman
correlation coefficient rs = -0.512, P = 0.061; S3 Fig), but did not correlate with the initial para-
sitemia (rs = 0.165, P = 0.412).
The next challenge consisted in selectively increasing parasite DNA yield for genome
sequencing. To this end, leukocyte-depleted P. vivax samples were cultured in vitro for up to
44 h to allow uninucleate trophozoites to mature to multinucleate blood-stage schizonts,
increasing parasite DNA content by4-fold [17]. We obtained enough template DNA for
library preparation and sequencing from 9 cultured samples, achieving 49.8–78.6× average
genome sequencing depth; 91.8–94.7% of the reads mapped to reference Sal-I genome
(Table 1). These results compared favorably with the coverage and percentage of reads map-
ping onto the reference P. vivax genome obtained with other different methods for clinical
sample preparation: (a) single CF-11 column filtration (0.8–42.1× depth and 0.4–27.8% map-
ping in 8 isolates from Colombia [35] and 4.2–28.1× depth and 18.3–55.4% mapping in 11 iso-
lates from Peru [36,37]), (b) double CF-11 column filtration (70–407× depth and 15.0–46.2%
mapping in 5 isolates from Cambodia and Madagascar [38]), (c) double CF-11 column filtra-
tion followed by in vitro schizont maturation (18–116× depth and 11.0–89.1% mapping in 22
isolates from Thailand and returning travelers [17]), and (d) in-situ hybridization for P. vivax
whole-genome capture in unfiltered samples (21.9–160.4× depth and 20.2–80.1% mapping in
5 isolates from Peru [16] and 34.8–118.2× depth and 19.6–39.7% mapping in 3 isolates from
East Asia [39]). Therefore, the sample preparation strategy described here allowed for high
sequence coverage and depth, but further comparisons are limited by the use of different next-
generation sequencing platforms across studies (Ion PGM and Ion Proton here and Illumina
in other studies).
Local and regional patterns of genome-wide diversity
We used the Ion PGM and Ion Proton platforms to generate between 17.8 and 23.9 million
sequence reads from 9 clinical samples of P. vivax from Brazil (Table 1). To explore local levels
of genomic diversity, our sequence data were combined with those from two P. vivax clinical
samples from Brazil that were previously obtained with Illumina platforms [11,14]. Sequence
reads from these additional samples (PV4 and Brazil32) covered 86.2% and 95.0% of the refer-
ence genome, respectively (S1 Table). Since all isolates from Brazil (n = 11) were collected
from sites within a radius of 120 km in the Amazon Basin (Fig 1), we define BRA as a local,
nearly sympatric P. vivax population. After applying stringent quality control filters to raw
sequence reads (see Methods), we uncovered 27,360 high-confidence single-nucleotide poly-
morphisms (SNPs) in the BRA population. The overall nucleotide diversity π was estimated at
5.6 x 10−4).
We next compared BRA sequence data with those from three other New World populations
of P. vivax: PER (n = 23), COL (n = 31), and MEX (n = 19) [11], from clinical isolates sampled
in sites shown in Fig 1. Two populations were geographically heterogeneous: PER samples
were collected in three departments (Loreto and Madre de Dios, both in the Amazon Basin,
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and Piura, on the northwestern Pacific coast), while COL samples came from four depart-
ments (Nariño, Valle del Cauca, and Choco´ along the Pacific Coast, and Co´rdoba, on the
Caribbean coast). MEX samples were from five different sites, but all in the southern state of
Chiapas (S1 Table). We characterized 94,122 biallelic SNPs passing our high-quality filters in
84 samples; 55.0% of them are located in intergenic regions, 8.8% in introns, and 36.2% in cod-
ing regions. Most (61.2%) coding SNPs were non-synonymous (nsSNPs), as previously found
in other regional P. vivax populations [14,38]. Unsurprisingly, the number of SNPs found in
each population was directly proportional to sample size, being lowest in BRA (n = 27,360)
and highest in COL (n = 57,262; Fig 2). Overall, 49,598 (52.3%) SNPs were unique to a popula-
tion (i.e., private) and 8,529 (9.1%) were shared by all populations (Fig 2). Of the 6,891 private
SNPs found in BRA, 40.0% mapped to coding sequences; 65.2% of the coding SNPs were non-
synonymous. PER and COL shared the highest number of SNPs (n = 28,667), followed by
COL and MEX (n = 24,107) (Fig 2).
Nucleotide diversity in PER (π = 5.2 x 10−4), COL (π = 5.5 x 10−4), and MEX (π = 6.2 x
10−4) was similar to that in BRA (π = 5.6 x 10−4), showing that the local BRA population was as
diverse as geographically heterogeneous sample sets from other American countries. Similar
levels of genome-wide nucleotide diversity were recently reported in P. vivax populations from
Colombia (π = 6.8 x 10−4; n = 8) [35], Thailand (π = 5.3 x 10−4; n = 88), Cambodia (π = 5.0 x
10−4; n = 19), and Indonesia (π = 5.0 x 10−4; n = 41) [14], but the differences across studies in
genome sequencing depth and criteria for defining high-quality SNPs limit such comparisons.
The frequency distribution of π values within 1-kb sequence windows across the genome
was quite similar in all countries (S4 Fig); the interquartile ranges (IQR) were 1.7 x 10−4 to 6.9
x 10−4 in BRA, 1.7 x 10−4 to 6.5 x 10−4 in PER, 1.3 x 10−4 to 6.6 x 10−4 in COL, and 1.9 x 10−4 to
Fig 2. Venn diagram showing the number of SNPs shared by P. vivax samples from Brazil (n = 11 isolates), Peru
(n = 23), Colombia (n = 31), and Mexico (n = 19).
https://doi.org/10.1371/journal.pntd.0005824.g002
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7.5 x 10−4 in MEX. All distributions were right-skewed, with asymmetry coefficients ranging
between 3.37 (BRA) and 3.84 (MEX).
We defined domains with the top 50 π values in a population as highly variable genomic
regions. They comprised, in addition to numerous sequences coding for hypothetical proteins,
gene families such as pst-a, fam-b, fam-d, and fam-e [40] and those coding for major parasite
antigens, such as the vir family (>300 genes, mostly in subtelomeric domains, on several chro-
mosomes), the serine repeat antigen (sera) family (13 genes on chromosome 4), the merozoite
surface protein (msp)-7 family (11 genes on chromosome 12), and the msp-3 family (11 genes
on chromosome 10) (S2 Table) (see also [11,14,36]).
These findings are not unexpected, since natural selection favors increased diversity in anti-
gen-coding genes to evade host immunity, but must be interpreted with caution because mis-
alignments of paralogous sequences may have inflated nucleotide diversity estimates in gene
families. We thus recalculated genome-wide π values after masking out subtelomeric domains
and the internal chromosomal regions comprising the sera, msp-3 and msp-7 gene families
[14], but this procedure affected our overall estimates very little; recalculated values were: BRA
(π = 5.5 × 10−4), PER (π = 5.2 × 10−4), COL (π = 4.7 × 10−4), and MEX (π = 5.2 × 10−4). The sin-
gle-copy msp-1 gene [41] also mapped to a highly variable genomic region in BRA. However,
our nucleotide diversity estimates for msp-1 may have been affected by likely sequence mis-
alignments in the numerous repetitive domains across this locus [42,43].
Signatures of selection and population expansion
The expected value for Tajima’s D is zero under a neutral model that assumes random mating,
no recombination, mutation-drift equilibrium, infinite sites, and constant population size.
High Tajima’s D values are usually due to balancing selection or recent population size
reduction, while negative D values are consistent with population size expansion or purifying
selection [44]. Although the P. vivax genomes from COL and PER were not part of a single
population (while BRA and MEX genomes are), the Tajima’s D distribution provides informa-
tion on how the pattern of mutations changes across the genome. All distributions of Tajima’s
D values in our populations were right-skewed, with asymmetry coefficients of 0.477 (BRA),
0.841 (PER), 0.902 (COL), and 0.412 (MEX) (Fig 3). Negative D values predominated in PER
(median: -0.439; IQR: -0.959 to -0.003) and COL (median: -0.466; IQR: -0.959 to 0.039), but
not in BRA (median: 0.026; IQR: -0.571 to 0.595) and MEX (median: 0.039; IQR: -0.724 to
0.748).
Interestingly, the genomic regions with the 50 lowest Tajima’s D values within each popula-
tion (threshold D values: -1.096 in BRA, -1.622 in PER, -1.724 in COL, and -1.376 in MEX)
comprised several hypothetical and housekeeping genes, but also members of gene families
such as vir, sera, msp-3, pst-a, and fam-a (S3 Table). Only two regions with low Tajima’s D val-
ues were shared by two populations; one had no annotated gene and the other had a gene cod-
ing for a hypothetical protein (S3 Table).
Similarly, the genomic regions with the 50 highest Tajima’s D values within each population
(cut-off values: 2.024 in BRA, 1.890 in PER, 2.078 in COL, and 2.407 in MEX) also comprised
several hypothetical and housekeeping genes and a few surface antigen genes (sera, circum-
sporozoite protein [csp], and msp-3) that may be under balancing selection (S4 Table). How-
ever, different genomic regions giving top 50 Tajima’s D values were typically found in each
population and only 11 of them (none comprising antigen-coding genes) were shared by two
or more populations. Whether the high Tajima’s D values found in certain domains are due
to random effects of the parasite’s demographic history or to balancing selection on specific
genes remains to be further examined in larger population samples.
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MAF distributions were L-shaped in all New World P. vivax populations (S5 Fig), similar
to patterns described for P. falciparum populations from sub-Saharan Africa [45,46]. The pro-
portion of SNPs with allele frequencies 0.1 were 51.6% in BRA, 66.3% in PER, 71.5% in
COL, and 55.1% in MEX. Despite the relatively small sample sizes, we interpret the clear pre-
dominance of negative Tajima’s D values in PER and COL and of rare alleles in all populations,
but mainly in PER and COL, as suggestive of a recent P. vivax population expansion in the
Americas. Data from an extensive mitochondrial genome analysis of local parasites are also
consistent with the demographic expansion hypothesis [47].
Genetic differentiation and population structure
P. vivax genomic sequences from the New World were previously shown to cluster mostly
according to their geographic origins, with the majority of MEX samples (that show more
extensive evidence of identity by descent) clustering together in PCA plots [11]. These findings
are particularly relevant to malaria-eliminating countries in the continent; if parasites can be
assigned by molecular genotyping to their countries of origin, locally acquired and imported
Fig 3. Frequency distribution of Tajima’s D values calculated within 1-kb windows of genomic sequence
in four New World populations of P. vivax. BRA = Brazil (n = 11 isolates), PER = Peru (n = 23),
COL = Colombia (n = 31), and MEX = Mexico (n = 19).
https://doi.org/10.1371/journal.pntd.0005824.g003
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infections can theoretically be easily distinguished. Moreover, genetic analysis can also help to
determine the likely origin of imported infections [10,48]. Accordingly, our PCA data revealed
a clear clustering of BRA samples, which were separated from other populations by principal
components C1 and C3 when the complete SNP data set was used. MEX was separated from
other populations mostly by C1 and C2, while PER and COL were less clearly differentiated
(Fig 4A).
Fig 4. Principal component analysis of the population structure of P. vivax in the New World. Panel A shows results using the
complete data set of 94,122 SNPs; panel B shows results obtained with a set of 37 segregating SNPs included in a previously described P.
vivax barcode [49]; and panel C shows results obtained with a hypothetical barcode comprising the 100 SNPs yielding the highest average
Wright’s fixation index FST values in pairwise comparisons of New World P. vivax populations. The SNPs used in the analysis shown in panel
C are listed in S5 Table. Samples are colored according to their geographic origin as shown in Fig 1. The percentage contributions of each
principal component (C1, C2, and C3) to overall variance were as follows: panel A, C1 = 22.27%, C2 = 14.15%, and C3 = 8.15%; panel B,
C1 = 19.93%, C2 = 12.03%, and C3 = 11.42%; and panel C, C1 = 21.36%, C2 = 10.93%, and C3 = 9.33%.
https://doi.org/10.1371/journal.pntd.0005824.g004
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Moreover, a rather similar sample clustering pattern was revealed by a standard, neighbor-
joining phylogenetic analysis (Fig 5). All BRA samples and most (16 of 19) MEX samples
formed well-supported clades, while PER and COL isolates spread across single- and multiple-
country clades.
Similar to PCA and phylogenetic analysis, the model-based clustering approach imple-
mented in ADMIXTURE software [33] also defined BRA and MEX as distinct populations
(S6A Fig, number of clusters K = 3) based on the whole genomic data set. PER and COL were
nearly indistinguishable. A similar analysis with 2 clusters did not differentiate MEX from
Fig 5. A neighbor-joining phylogenetic tree with 1,000 bootstrap pseudoreplicates obtained with genomic sequences of P. vivax
isolates from Brazil (n = 11 isolates), Peru (n = 23), Colombia (= 31), and Mexico (n = 19). Branch tips were colored according to the
geographic origin of samples, as shown in Fig 1. Grey circles indicate internal nodes with > 70% bootstrap support.
https://doi.org/10.1371/journal.pntd.0005824.g005
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COL (S6A Fig, number of clusters K = 2). ADMIXTURE analysis using a curtailed data set
(12,762 unlinked SNPs) allowed a poor differentiation between populations (S6B Fig, number
of clusters K = 2 or 3). Not surprisingly, the most geographically homogeneous samples (BRA
and MEX) formed well-defined clusters.
We next tested whether a recently described P. vivax SNP barcode [49] would be able
to correctly assign New World isolates to their countries of origin. Of the 42 SNPs
originally included in the barcode, five did not segregate in our populations. PCA with
the remaining 37 SNPs was unable to cluster our parasite populations by their countries
of origin (Fig 4B).
The overall pairwise differentiation between populations, estimated using FST averaged
across the entire genome, was directly proportional to the geographic distance between sites,
being lowest between COL and PER and highest between BRA and MEX (Table 2). Among
the 100 SNPs with the highest average pairwise FST estimates, only two mapped to antigen-
coding genes (both to sera gene paralogs on chromosome 4); all others were either noncoding
SNPs or mapped to genes encoding hypothetical or housekeeping proteins (S5 Table). We
next tested whether these 100 SNPs with the top FST values could separate New World popula-
tions more efficiently than the complete genome-wide SNP set (compare Fig 4A and 4C) and
the currently available 42-SNP P. vivax barcode [49] (compare Fig 4B and 4C). These results
suggest that regional SNP barcodes could be further explored to track the geographic origin of
P. vivax samples in the Americas.
Nucleotide substitutions and antimalarial drug resistance
Our genomic sequence data enabled the identification of SNPs mapping to several P. vivax
genes known or suspected to be involved in antimalarial drug resistance (Table 3). We found
nonsynonymous mutations at the dihydrofolate reductase-thymidylate synthase (dhfr) locus
previously associated with pyrimethamine resistance (S58R and S117N) almost exclusively in
COL (see also [35]) and PER (see also [37]), whereas antifolates are no longer recommended
in these countries; two previously undescribed SNPs (H99N and H99R) were also found in
COL. The dihydropteroate synthase (dhps) SNP A383G, associated with sulfadoxine resistance,
was also observed in COL and PER (see also [35]), with the M205I change being found only in
PER (see also [36]). Little or no polymorphism in dhfr and dhps genes was observed in BRA
and MEX, likely reflecting differences in sulfadoxine-pyrimethamine use across countries in
the region. Although pyrimethamine and sulfadoxine has never been recommended as a treat-
ment for P. vivax infection, they may have been used to treat patients co-infected with P. falcip-
arum and P. vivax, exposing the latter parasite to these drugs and likely selecting for resistant
phenotypes. Moreover, the frequent use of sulfonamides to treat co-occurring, unrelated
(mostly bacterial) infections may have selected sulfa-resistant strains in malaria parasite carri-
ers from some of these countries.
Non-synonymous substitutions were also characterized in the multidrug resistance 1 pro-
tein (mdr1) gene, including two previously undescribed (L186W and F1070L) and six
Table 2. Pairwise differentiation between populations, estimated using the Wright’s fixation index FST averaged across all loci, in Plasmodium
vivax populations from Brazil, Peru, Colombia, and Mexico.
Country Brazil Peru Colombia Mexico
Brazil 0.037 0.055 0.092
Peru 0.030 0.047
Colombia 0.025
https://doi.org/10.1371/journal.pntd.0005824.t002
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previously reported SNPs (V221L, M908L, T958M, Y976F, and F1076L [50]). The Y976F
change, originally believed to confer chloroquine resistance (CQR) in Southeast Asia and Mel-
anesia [24], occurred in a single BRA sample whose CQR phenotype could not be determined
(Table 2). Interestingly, we found no coding changes in the chloroquine resistance transporter
Table 3. Nonsynonymous single-nucleotide polymorphism (SNPs) detected in drug resistance genes by whole-genome sequencing in Plasmo-
dium vivax isolates from Brazil, Peru, Colombia, and Mexico.
Gene Chromosome Amino acid change No. (%) samples with SNP per country
Brazil Peru Colombia Mexico
dhfr (PVX_089950) 5 S58R 0 (0.0%) 2 (8.7%) 5 (16.1%) 0 (0.0%)
H99N 0 (0.0%) 0 (0.0%) 2 (6.4%) 0 (0.0%)
H99R 0 (0.0%) 0 (0.0%) 2 (6.4%) 0 (0.0%)
S117N 1 (9.1%) 4 (17.4%) 17 (54.8%) 0 (0.0%)
dhps (PVX_123230) 14 M205I 0 (0.0%) 1 (4.3%) 0 (0.0%) 0 (0.0%)
A383G 0 (0.0%) 1 (4.3%) 1 (3.2%) 0 (0.0%)
mdr1 (PVX_080100) 10 L186W 0 (0.0%) 1 (4.3%) 0 (0.0%) 0 (0.0%)
V221L 0 (0.0%) 2 (8.7%) 0 (0.0%) 0 (0.0%)
M908L 0 (0.0%) 8 (34.8%) 3 (9.7%) 0 (0.0%)
T958M 0 (0.0%) 9 (39.1%) 6 (19.3%) 4 (21.0%)
Y976F 1 (9.1%)a 0 (0.0%) 0 (0.0%) 0 (0.0%)
F1070L 0 (0.0%) 2 (8.7%) 0 (0.0%) 0 (0.0%)
F1076L 1 (9.1%)a 1 (4.3%) 0 (0.0%) 0 (0.0%)
mrp1 (PVX_097025) 2 T259R 0 (0.0%) 1 (4.3%) 13 (56.5%) 12 (63.2%)
T282M 0 (0.0%) 0 (0.0%) 5 (16.1%) 0 (0.0%)
K542E 0 (0.0%) 0 (0.0%) 1 (3.2%) 0 (0.0%)
Q906E 0 (0.0%) 7 (30.4%) 9 (29.0%) 0 (0.0%)
L1282I 0 (0.0%) 0 (0.0%) 2 (6.4%) 0 (0.0%)
Y1393D 3 (27.3%)b 8 (34.8%) 0 (0.0%) 2 (10.5%)
G1419A 1 (9.1%)c 5 (21.8%) 2 (6.4%) 1 (5.3%)
V1478I 2 (18.2%)d 4 (17.4%) 1 (3.2%) 1 (5.3%)
I1480V 0 (0.0%) 0 (0.0%) 1 (3.2%) 0 (0.0%)
T1525I 0 (0.0%) 0 (0.0%) 1 (3.2%) 0 (0.0%)
H1586I 0 (0.0%) 4 (17.4%) 0 (0.0%) 0 (0.0%)
mrp2 (PVX_124085) 14 S1701L 0 (0.0%) 1 (4.3%) 0 (0.0%) 0 (0.0%)
T1698K 0 (0.0%) 2 (8.7%) 0 (0.0%) 5 (26.5%)
P1600H 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (5.3%)
Q1419E 0 (0.0%) 2 (8.7%) 3 (9.7%) 3 (6.9%)
N1263Y 0 (0.0%) 2 (8.7%) 1 (3.2%) 0 (0.0%)
P1196S 0 (0.0%) 0 (0.0%) 1 (3.2%) 4 (21.0%)
G1166E 0 (0.0%) 0 (0.0%) 0 (0.0%) 5 (26.5%)
A1106S 0 (0.0%) 0 (0.0%) 3 (9.7%) 7 (37.1%)
V1022M 1 (9.1%) 4 (17.4%) 2 (6.4%) 0 (0.0%)
S681I 0 (0.0%) 0 (0.0%) 5 (16.1%) 0 (0.0%)
R294M 1 (9.1%) 3 (12.9%) 16 (51.2%) 12 (63.6%)
aThe sample from Brazil carrying these two mutations (#18) was not tested for chloroquine resistance.
bTwo of three samples (#20 and #207) carrying this mutation were characterized as chloroquine-sensitive using an ex-vivo schizont maturation test (IC50 =
14.5 and 46.7 mM, respectively); the third sample (#Brazil32) [11] was not tested for chloroquine resistance.
cThe sample from Brazil carrying this mutation (#207) was characterized as chloroquine-sensitive (IC50 = 46.7 mM)
dOne sample from Brazil carrying this mutation (#32) was characterized as chloroquine-sensitive (IC50 = 20.5 mM); the second sample (#Brazil32) [11] was
not tested for chloroquine resistance.
https://doi.org/10.1371/journal.pntd.0005824.t003
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ortholog (crt-o) gene (PVX 087980), whose ortholog in P. falciparum displays a key non-syn-
onymous substitution leading to CQR [51].
Five of 12 mutations found at the multidrug resistance associated protein 1 (mrp1 [PVX
097025]) locus, which codes for an ATP-cassette binding (ABC) transporter putatively
involved in antimalarial drug efflux [52], had been described in a clinical sample from Peru
(L1282I, Y1393D, G1419A, V1478I, and H1586I [36]). Similarly, six of 11 had been previously
described in Colombia (Q1419E, P1196S, A1106S, V1022M, S681I, R294M [35]) and six in
Peru (S1701L, T1698K, Q1419E, A1106S, V1022M, and R294M [37]), in multidrug resistance
associated protein 2 gene (PVX_124085). The antimalarial drug-resistance phenotype (if any)
associated with these mutations remains undetermined.
Linkage disequilibrium
Here we found a sharp LD decline within 100 bp of distance between pairs of SNPs in BRA
and MEX, with very low LD in COL and negligible LD in PER (Fig 6). Interestingly, the LD
decay in BRA and MEX populations, originating from the sites with the lowest malaria trans-
mission [53], was even faster than that described for P. vivax populations from Southeast Asia,
where P. vivax endemicity is substantially higher [14], and that described for P. falciparum
populations from areas of much higher endemicity in Sub-Saharan Africa [54, 55, 56] and
Southeast Asia [56]. These results are consistent with a very high outcrossing rate in P. vivax
populations and imply that SNP array-based genome-wide association studies (GWAS) would
require a very high marker density (inter-marker distance < 100 bp) to help find genetic loci
that determine phenotypes of interest, such as drug resistance and virulence, in BRA and MEX
populations. SNP-based association studies are unlikely to be successful in PER and COL pop-
ulations, given the negligible LD. In contrast, P. falciparum populations from the Pacific Coast
Fig 6. Linkage disequilibrium (LD) decay with increasing distance between SNPs on the same
chromosome. Solid lines show median r2 estimates for SNPs along the same chromosome plotted against
the inter-marker physical distance for Brazil (pink), Peru (green), Colombia (blue), and Mexico (orange).
Dotted lines show the background genome-wide LD (median r2 estimates for unlinked SNPs—those mapping
to different chromosomes).
https://doi.org/10.1371/journal.pntd.0005824.g006
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of Colombia showed a much more gradual LD decline, reaching background LD levels only at
an inter-marker distance of 240 kb [57].
Conclusions
We found high genome-wide diversity and relatively little geographic structure in P. vivax
populations from areas of relatively low malaria transmission in the Americas. These find-
ings contrast with the low genetic diversity and clear subdivision into local, highly divergent
populations that is typical of New World populations of P. falciparum [57–61]. Interestingly,
local P. vivax populations are nearly as polymorphic as their P. falciparum counterparts
from Africa [45,46,54] and their P. vivax counterparts from Southeast Asia [11,14]. More-
over, the low levels of between-population differentiation in P. vivax from the Americas are
reminiscent of those in P. falciparum populations from hyperendemic sub-Saharan Africa
[45,46,59, 62].
Demographic history might explain, at least in part, the observed differences between P.
vivax and P. falciparum populations from the New World. The original diversity of the ances-
tral P. falciparum population may have been partially lost during (a) its migration to the Amer-
icas in post-Columbian times [63] followed by the adaptation to entirely different local vectors
[64], (b) recent selective sweeps driven by antimalarial drugs, such as chloroquine [65] and
pyrimethamine [66], and (c) local extinctions and clonal expansions following eradication
attempts in the Americas between the mid-1950s and late 1960s [53,60]. These events would
have resulted in small and fragmented, mostly inbred P. falciparum populations being scat-
tered throughout the region. The significantly greater genome-wide diversity currently found
in P. vivax populations worldwide, compared with P. falciparum [11,67], suggests that (a) this
species retained more ancestral diversity than P. falciparum when transferred from apes to
humans and following subsequent spread out of Africa and/or (b) P. vivax is simply older than
P. falciparum and therefore has accumulated more mutations over time. Moreover, these spe-
cies might also differ in the ways they colonized the New World. The high diversity of present-
day P. vivax lineages across this continent is consistent with an admixture of parasite lineages
originating from geographically diverse regions [5, 7, 47], including now extinct European lin-
eages [12]. The success of colonization events and the recombination between these intro-
duced strains may have been favored by the ability of P. vivax to stay dormant in the liver as
hypnozoites, prolonging the duration of parasite carriage in human hosts and increasing the
probability of superinfections leading to the co-occurrence of genetically diverse clones that
may recombine once transmitted to mosquito vectors. Moreover, genome-wide P. vivax diver-
sity in the region appears to have been little affected by recent selective sweeps driven by pyri-
methamine [35,37] in Brazil and Colombia. Interestingly, P. vivax resistance to chloroquine
remains relatively infrequent in the New World [68] and is unlikely to have induced a major
selective sweep in local parasites.
Improved methods for clinical sample preparation and next-generation sequencing now
enable further genome-wide analyses of additional P. vivax isolates from the New World, to
test the demographic scenarios suggested by our data.
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S1 Fig. Single-step filtering procedure used to remove leukocytes from clinical blood sam-
ples in a field laboratory. A, BioR 01 Plus leukocyte depletion filter (Fresenius Kabi, Bad
Homburg, Germany). B and C, cutting off with a scissor, under sterile conditions, the tubing
connecting the filtering device to the 400-ml blood storage bag and the adapter. D, use of filter-
ing device in a laminar flow hood, indicating how the blood sample is introduced and
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K = 3 clusters with all 94,122 high-quality SNPs (panel A) or a curtailed set of 12,762 SNPs that
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differentiation among populations.
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